Kornimate/medical-research-clean huggingface dataset:
analysis of the diagnostic performance of lacrydiag, a new analyzer of the ocular surface in the dry eye

Conditions: Dry Eye

Summary: lacrydiag is a new conformity european (ce) marked diagnostic imaging device devoted to the analysis of the ocular surface. it is an "all in one" device that provides 4 data: non-invasive break-up time (non-invasive break-up-time (nibut) without fluorescein eye drop); height of the tear meniscus (tm); an infrared image of the meibomian glands; a picture of the lacrimal film by interferometry. it's performance will be compare between in diagnosing dry eye syndrome with the standard clinical evaluation, in 80 patients suffering from dry eye diseases and followed at the consultation of the ophthalmology department of the university hospital of saint-etienne.

the primary purpose of this study is to compare the value of break-up-time (but) between non-invasive break-up-time (nibut) measured by lacrydiag and standard break-up-time (sbut) measured by usual practice.

Eligibility criteria:
inclusion criteria: * affiliates or beneficiaries of social security scheme * with dry eye of any cause, diagnosed with conventional means * signed informed consent exclusion criteria: * major blepharospasm * serious illness preventing participation according to investigator * allergy to fluorescein * pregnant or / and breastfeeding women * under guardianship, curatorship or safeguard of justice * unable to express their consent * person in emergency situation

Keywords: dry eye lacrydiag fluorescein break-up time (but) schirmer test lacrimal film oxford score meibomian gland tear meniscus (tm) non invasive break-up time (nibut)
pressure gradient vs. flow relationships in patients with symptomatic valvular aortic stenosis

Conditions: Aortic Valve Stenosis

Summary: the objective of the present study is to investigate to hemodynamic profile at rest and during peak exercise of patients with suspected severe aortic stenosis and to compare flow- and pressure changes between high gradient patients and low gradient patients.


Eligibility criteria:
inclusion criteria: * patients with suspected severe as scheduled for evaluation for aortic valve intervention: * lvef \> 50 % * ava \< 1.0 cm2 * symptomatic - at least equivalent to nyha functional class ii exclusion criteria: * congenital heart disease * severe coronary artery disease (main stem, proximal lad or 3 vessel disease) * moderate or severe aortic valve regurgitation * moderate or severe mitral valve regurgitation or stenosis * moderate or severe pulmonary valve regurgitation or stenosis * moderate or severe tricuspid valve regurgitation or stenosis * severe pulmonary hypertension (tricuspid valve pressure gradient of 60 mmhg) * right ventricular dysfunction (tapse \< 17 mm) * restrictive cardiomyopathy or cardiac amyloidosis * constrictive pericarditis * inability to perform supine bicycle exercise
blood pressure and glucose lowering diet for taiwanese

Conditions: Hypertension

Summary: prevalence rates of hypertension and diabetes are high in taiwan. little attention is given to evidence-based dietary therapy in taiwan. patients, after confirmed diagnosis, are mostly prescribed with medications without comprehensive instructions on dietary therapy. dash diet has been proven to be an effective dietary approach to reduce blood pressure for hypertension patients in us. however, dietary difference and patient profiles across countries are evident. in addition, hypertensive patients are often combined with hyperglycemia. carbohydrate burden of dash diet may be higher than most dietitians desire. therefore, the investigators in tend to design a taiwanese dash diet and a lower carbohydrate dash diet and test their efficacy on both blood pressure and fasting glucose lowering.


Eligibility criteria:
inclusion criteria: * age 20-65 years, weight 50-80 kg(±5kg) * two blood pressure readings and fasting blood glucose measurements: 1. fasting blood glucose of 100-125 ml/dl and not using antidiabetic medication. 2. systolic blood pressure of 130-159 mmhg or diastolic blood pressure of 85-99 mmhg and not using antihypertensive medication. exclusion criteria: * (a) taking blood glucose lowering, antihypertensive or oral steroid medications. (b) history of stroke, cardiovascular disease, abnormal liver function, cancer, stomach ulcer, inflammatory bowel disease or other chronic diseases that will influence the diet of participants. (c) major surgery in the past year or about to undergo major surgery. (d) is the holder of a major illness card. (e) takes antipsychotics. (f) harmful drinker (more than 14 drinks per week) (g) has food allergies or food intolerance. (h) pregnant or breastfeeding. (i) unwilling to cease intake of vitamin or mineral supplements or antacids containing magnesium or calcium for the duration of the study. (j) other medications or physiological states influencing the absorption of nutrients. (k) other individuals deemed unsuitable to participate in the intervention by their treating physician.

Keywords: hypertension
ultrasound study of the submentonian musculature and its relationship in dysphagia

Conditions: Dysphagia, Oropharyngeal; Deglutition Disorders; Mechanical Ventilation Complication

Summary: acquired dysphagia is one of the most frequent complications suffered by patients in intensive care units (icu) after orotracheal extubation. ultrasound has proven to be a useful method in the morphological and kinematic exploration of the main swallowing structures. aim: to evaluate, through ultrasound procedures, the evolution of the morphology of the tongue and muscles of the floor of the mouth and the hyolaryngeal kinematics in patients intubated \>48h and to correlate these measurements with the possible development of acquired dysphagia. the incidence of dysphagia and icu acquired weakness (icuaw) in subjects with \>48h of intubation and the relative risk factors associated with baseline characteristics and clinical variables will be described. methodology: design: single-center cohort study (ramón y cajal university hospital). participants: subjects \>18 years old, admitted to an intensive care unit (icu), with \>48 hours of orotracheal intubation who meet eligibility criteria. outcomes: the study of socio-demographic and clinical variables related to icu admission will be included. the physical function variables will be analyzed through the medical research council (mrc) and functional status score (fss), as well as swallowing function variables through the volume-viscosity swallow (vvs-t) and functional oral intake scale scales. (fois) and gugging swallowing screen (guss). measurements will be made of the thickness and echogenicity of the submental and tongue muscles, as well as hyolaryngeal kinematics


Eligibility criteria:
inclusion criteria: * • subjects \>18 years old. * having received an episode of orotracheal intubation for \>48h exclusion criteria: * • congenital or acquired conditions of the central nervous system (cns) such as stroke, traumatic brain injury, parkinson's, multiple sclerosis, amyotrophic lateral sclerosis (als) or any other condition that may bias the attribution of dysphagia to factors other than exclusively clinical ones. * involvement of the cranial nerves or the peripheral nervous system (pns) as well as diseases of the neuromuscular junction such as myasthenia gravis or any other condition that may bias the attribution of dysphagia to other factors that are not exclusively clinical. * neck morphology incompatible with exploration through ultrasound procedures. * secondary musculoskeletal injuries, including vertebral fractures, unstable extremity fractures or any condition that requires absolute bed rest as prescribed by a doctor. * malignant tumor lesions or previous head and/or neck surgeries. * medical-surgical history due to pathology of the larynx, oropharynx and/or esophagus. * diagnosis of dysphagia or swallowing disorders prior to the intubation episode with imv. * patients unable to eat orally, at least partially. * known prior cognitive impairment upon admission to the icu.

Keywords: dysphagia ultrasonography deglutition disorders diagnostic imaging mechanical ventilation
exercise, oxidative stress and hiv

Conditions: HIV Infections

Summary: the purpose of this study is to compare oxidative stress markers and the immunologic characteristics of hiv-infected and non-hiv subjects during a bout of moderate aerobic exercise followed by resistance exercises


Eligibility criteria:
inclusion criteria: * hiv group:without contraindications for exercise training; to highly active antiretroviral therapy (haart) for at least 6 months before enrollment; be classified as low level of physical activity by international physical activity questionnaire (ipaq) and did not use antioxidant supplements. * control group:negative result for hiv-1 test and the other criteria described above exclusion criteria: * subjects with previous history of cardiovascular and neurological disease, diabetes, dyslipidemia, tobacco using, physical disability and pregnant women were excluded from the study.
eeva system imaging study

Conditions: Infertility

Summary: the purpose of this clinical trial is to collect imaging data on embryos followed to blastocyst stage (day 5-6) for ongoing development and validation of the eeva system.

the purpose of this clinical trial is to collect imaging data on embryos followed to blastocyst stage (day 5-6) for ongoing development and validation of the eeva system. primary objectives include: to collect imaging data on embryos followed to blastocyst stage (day 5-6) secondary objectives include: to collect enrollment data: demographics, ivf and pregnancy history to collect day 3, day 5 and day 6 embryo morphology data to collect pregnancy test and outcome data to collect pre-implantation genetic screening (pgs) data (if applicable) to collect frozen embryo transfer (fet) data (if applicable)

Eligibility criteria:
inclusion criteria: * at least 18 years of age * women undergoing in vitro fertilization treatment using their own eggs * fresh or frozen blastocyst (day 5-6) transfer * at least 5 diploid (2pn) embryos at fertilization check * willing to have all 2pn embryos imaged by eeva * willing to comply with study protocol and procedures * willing to provide written informed consent exclusion criteria: * freeze-all due to ovarian hyperstimulation syndrome (ohss) * use of donor egg / gestational carrier * fertilization using surgically removed sperm * history of cancer * assisted hatching (ah) on day 3
calcium, dairy, and body fat in adolescents

Conditions: Obesity; Energy Metabolism

Summary: lifestyle choices,including diet,are conducive to healthy body weights in children. dairy products and calcium supplementation have been associated with moderation of body weight and body fat. this study was designed to test the following hypotheses with overweight and obese adolescents consuming a controlled diet: * dietary calcium supplementation as calcium carbonate or dairy calcium modulates energy balance in adolescents. * increased calcium in the diet of adolescents will increase fecal fat excretion and thereby decrease fat absorption. * calcium and dairy product supplementation will increase lipid oxidation resulting in an increase in energy expenditure.

subjects will consume a controlled diet containing 800 mg calcium for two three week periods. during one period they will also receive a frozen ice cream like product (smoothie) twice a day based on soy protein that contains no additional calcium. during the other period they will receive a similar product twice a day based on either dairy protein that contains 650 mg calcium or based on soy protein that contains 650 mg calcium as calcium carbonate

Eligibility criteria:
inclusion criteria: * over weight (\>85th percentile bmi for age) exclusion criteria: * \> 180% of ideal body weight for height * malabsorptive disorders * bone disease * liver disease * kidney disease * anemia * smoking or illegal drugs * oral contraceptives * pregnancy * medications that influence calcium metabolism

Keywords: calcium carbonate obesity dairy energy expenditure
cognitive behavioral and faith fellowship to improve thy health

Conditions: Depression

Summary: investigators will examine the efficacy of a faith-based depression intervention, in reducing symptoms of depression among african american adults in wisconsin. twelve church groups, each with 10 people (n=120) will be invited to participate. this intervention will be the first evidence-based, faith-based intervention designed for african americans if validated.

the randomized stepped wedge design (r-swd) is a type of cluster randomized controlled trial in which the unit of randomization is a cluster (e.g., church groups with a group of 10 participants), not individual participants. at the start of a r-swd, all clusters begin as control groups. at certain time points during the course of the trial, some of the clusters are randomly selected to be switched to the cognitive behavioral faith fellowship to improve thy health (cb-faith) treatment, with all clusters eventually crossing over to receive the treatment. primary aim 1: examine efficacy of cb-faith in reducing symptoms of depression. secondary aim 1: examine moderating effects of religiosity on treatment effectiveness. secondary aim 2: evaluate satisfaction with cb-faith delivered in church settings. impact: cb-faith is poised to be the first evidence-based faith-based depression intervention designed for african american adults with depression. this community-prioritized research and transformative intervention has potential to reduce depression symptoms, reduce mental health disparities and advance health equity. given the impact of covid-19 pandemic, cb-faith is critically needed.

Eligibility criteria:
inclusion criteria: * self-identify as an african american man or woman * are ages 18 and older * have symptoms of major depressive disorder, as evidenced by score of 10 and higher from the patient health questionnaire-9 (phq-9). exclusion criteria: * major psychotic illnesses, such as schizophrenia; * current participation in psychotherapy * current suicidal ideations (trained staff will conduct a suicide risk assessment and facilitate referral for appropriate care). * medication stabilization. eligible participants who report recent changes to their psychiatric medications (i.e., initiation of a new medication, change in dose or type of medication) will delay their study enrollment for a stabilization period of 4 weeks. baseline data collection will be re-administered * alcohol or drug dependence - those with alcohol or other drug dependence who have been clean and sober for 3 months will not be excluded

Keywords: faith-based intervention
vitamin d deficiency among women with unexplained infertility

Conditions: Case Control Study

Summary: does vitamin d is more deficient in women with unexplained infertility than in fertile pregnant women or not?

the study will be done on women with unexplained infertility as a case group and fertile pregnant women as control group to detect if there's a difference in serum level of vitamin d between two groups which will help in the future for curing unexplained infertility women.

Eligibility criteria:
inclusion criteria: * women with unexplained infertility. * pregnant fertile women as control group. exclusion criteria: * • endocrinopathies such as (diabetes mellitus, thyroid disorders, parathyroid disorders and hyperprolactinemia), cardiovascular related diseases, severe infection, malignancies and concomitant diseases contribute to vit d deficiency. * women with ovulatory factor like pcos,anovulation and poor ovarian reserve are excluded. * women with endometriosis are excluded. * women with autoimmune diseases like antiphospholipid antibodies or lupus erythematosus are excluded. * documented uterine anomalies, tubal factor, cervical factor and other local causes of infertility. * male factor of infertility is excluded. * bone and metabolic disease, liver diseases and kidney related diseases.
possible predictors of mortality based on covid-19 for patients under 50 years old: a multi-center experience of istanbul

Conditions: Covid-19; Risk Factor, Mortality

Summary: covid-19, which emerged in china in december 2019, has become a pandemic with its spread to many countries of the world. mortality rates of covid-19 pandemics vary between countries. it is known that mortality based on covid-19 is higher in old population. therefore the aim of this study to analyze the experience of 7 governmental hospitals in terms of patient characteristics, possible risk factors of mortality based on covid-19.

covid-19, which emerged in china in december 2019, has become a pandemic with its spread to many countries of the world. mortality rates of covid-19 pandemics vary between countries. it is known that mortality based on covid-19 is higher in old population. although several factors defined to be effective on this 'age depending factors' regional differences should be assessed deeply to clarify both the etiology and epidemiology. therefore the aim of this study to analyze the experience of 7 governmental hospitals in terms of patient characteristics, possible risk factors of mortality based on covid-19.

Eligibility criteria:
inclusion criteria: * accepted to participate * patients who were proven to have covid-19 exclusion criteria: * declined to participate * patients whose age under 18 or more than 50 years
immunochemotherapy ± salvage chemoradiation for local recurrence of esophageal squamous cell carcinoma after definitive chemoradiotherapy

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Summary: the combination of programmed death receptor 1 (pd-1) inhibitors with chemotherapy has been recognized for the treatment of advanced and metastatic esophageal squamous cell carcinoma (escc). to the best of our knowledge, there is no published report to date which analyzes the efficacy and safety of this regimen in the treatment of locally primary-recurrent escc patients after definitive chemoradiotherapy or radiotherapy only. this is a prospective clinical study designed to enroll 79 patients. the study will focus on those who have attained a complete response (cr) subsequent to definitive chemoradiotherapy or radiotherapy and have a histologically proven in-field recurrence, with no distant metastases. these patients will receive treatment with a pd-1 inhibitor combined with monotherapy chemotherapy for 4 cycles, followed by a 2-year maintenance treatment with pd-1 inhibitors. during this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (pd) have the option to undergo salvage radiotherapy in conjunction with a dual-agent chemotherapy for 5 cycles. the primary endpoint of is 2-year after recurrence survival (ars) rate. the secondary endpoints include the progression-free survival (pfs) and safety.


Eligibility criteria:
inclusion criteria: -1.age ≥18 years, regardless of gender. 2.pathologically confirmed local recurrence of esophageal squamous cell carcinoma after definitive chemoradiotherapy. 3.with or without regional lymph node metastasis, but no distant metastasis. 4.ineligible for surgery or refusal to undergo surgical intervention. 5.tolerance to chemotherapy, radiotherapy, and immunotherapy. 6.ecog performance status 0-2. 7.life expectancy ≥3 months. 8.no severe hematopoietic, cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency. exclusion criteria: * 1. esophageal perforation or hematemesis. 2.distant metastasis in patients after definitive chemoradiotherapy. 3.history of drug abuse, chronic alcoholism, or hiv/aids. 4.myocardial infarction within ≤6 months. patients with myocardial infarction \>6 months ago must undergo myocardial thallium scan to confirm absence of myocardial ischemia and obtain cardiologist approval for chemotherapy. 5.uncontrolled seizures or psychiatric disorders impairing decision-making capacity. 6.severe allergic history or hypersensitivity. 7.other conditions deemed unsuitable for study participation by the investigator.

Keywords: esophageal squamous cell carcinoma local recurrence at the primary tumor site programmed cell death protein 1 salvage chemoradiotherapy immunochemotherapy
pilot study to test the effects of arctiva on mild to moderate eczema

Conditions: Atopic Dermatitis Eczema

Summary: up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study investigational product for 4 weeks.

this will be a 4-week single arm study. this study will be executed by one clinical research company in one research center accruing 30 subjects with mild to moderate eczema/atopic dermatitis. patients ages 18-75, will be enrolled. subjects that are enrolled will be placed on locus's over the counter cream "arctiva" twice per day for 4 weeks.

Eligibility criteria:
inclusion criteria: * male and female;18-75 years of age * have a clinical diagnosis of mild to moderate eczema or atopic dermatitis * signed and dated written informed consent in accordance with good clinical practice (gcp) and local legislation prior to the start of any screening procedure exclusion criteria: * patients using topical corticosteroids steroidal creams and other agents within 7 days prior to first dose of trial eczema treatment. * use of systemic corticosteroids or other agents for atopic dermatitis within 4 weeks prior to first dose of trial treatment. * active bacterial, viral, or fungal skin infections